Conflicts of interest Dr Horn consults with the International Psoriasis Council; Dr Domm has nothing to disclose; Dr Katz was an employee of Stiefel Laboratories; Dr Lebwohl has been a consultant and/or speaker for Abbott, Amgen, Astellas, Centocor, Galderma, Genentech, Medicis, Novartis, Pharmaderm, Sanofi-Aventis, Stiefel, Triex, Warner Chilcott, and York Pharma; Professor Mrowietz has been a consultant, investigator, and/or speaker for Leo Pharma; Professor Kragballe has been a consultant, investigator, and/or speaker for Abbott, Janssen-Cilag, Leo Pharma, Merck-Serono, Schering Plough, Wyeth, and Symphogen. Unrestricted funding for this work was provided by Galderma Laboratories, Leo Pharma, Medicis, and Warner Chilcott. These companies had no influence on the content or construction of this paper.
Topical corticosteroids in psoriasis: strategies for improving safety
Article first published online: 3 JUL 2009
© 2009 The Authors. Journal compilation © 2009 European Academy of Dermatology and Venereology
Journal of the European Academy of Dermatology and Venereology
Volume 24, Issue 2, pages 119–124, February 2010
How to Cite
Horn, E., Domm, S., Katz, H., Lebwohl, M., Mrowietz, U., Kragballe, K. and for the International Psoriasis Council (2010), Topical corticosteroids in psoriasis: strategies for improving safety. Journal of the European Academy of Dermatology and Venereology, 24: 119–124. doi: 10.1111/j.1468-3083.2009.03358.x
- Issue published online: 7 JAN 2010
- Article first published online: 3 JUL 2009
- Received: 31 March 2009; Accepted: 27 May 2009
- topical therapy
Corticosteroids are a mainstay of topical therapy for psoriasis. While efficacious and relatively safe when used carefully, the potential for side effects, notably skin atrophy and adrenal suppression, have been associated with excesses in potency, prolonged or widespread use. The International Psoriasis Council Working Group on Topical Therapy has reviewed the efficacy and safety of topical corticosteroids and recommends strategies for safe, long-term use of these agents.